The structural basis of PTEN regulation by multi-site phosphorylation.


Journal

Nature structural & molecular biology
ISSN: 1545-9985
Titre abrégé: Nat Struct Mol Biol
Pays: United States
ID NLM: 101186374

Informations de publication

Date de publication:
10 2021
Historique:
received: 05 09 2020
accepted: 26 08 2021
entrez: 9 10 2021
pubmed: 10 10 2021
medline: 23 11 2021
Statut: ppublish

Résumé

Phosphatase and tensin homolog (PTEN) is a phosphatidylinositol-3,4,5-triphosphate (PIP

Identifiants

pubmed: 34625746
doi: 10.1038/s41594-021-00668-5
pii: 10.1038/s41594-021-00668-5
pmc: PMC8549118
mid: NIHMS1747676
doi:

Substances chimiques

PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67

Banques de données

Dryad
['10.5061/dryad.dfn2z34zh']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

858-868

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM136859
Pays : United States
Organisme : NIGMS NIH HHS
ID : F32 GM120855
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221830
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008403
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA074305
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM078221
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA242461
Pays : United States
Organisme : NIGMS NIH HHS
ID : K99 GM130961
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB002026
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM080189
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Maehama, T. & Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375–13378 (1998).
pubmed: 9593664 doi: 10.1074/jbc.273.22.13375
Worby, C. A. & Dixon, J. E. Pten. Annu. Rev. Biochem. 83, 641–669 (2014).
pubmed: 24905788 doi: 10.1146/annurev-biochem-082411-113907
Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
pubmed: 9072974 doi: 10.1126/science.275.5308.1943
Chalhoub, N. & Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127–150 (2009).
pubmed: 18767981 doi: 10.1146/annurev.pathol.4.110807.092311 pmcid: 2710138
Manning, B. D. & Toker, A. AKT/PKB signaling: navigating the network. Cell 169, 381–405 (2017).
pubmed: 28431241 doi: 10.1016/j.cell.2017.04.001 pmcid: 5546324
Janku, F., Yap, T. A. & Meric-Bernstam, F. Targeting the PI3K pathway in cancer: are we making headway? Nat. Rev. Clin. Oncol. 15, 273–291 (2018).
pubmed: 29508857 doi: 10.1038/nrclinonc.2018.28
Kotelevets, L., Trifault, B., Chastre, E. & Schott, M. G. H. Posttranslation regulation and conformational plasticity of PTEN. Cold Spring Harb. Perspect. Med. 7, a036095 (2020).
doi: 10.1101/cshperspect.a036095
Campbell, R. B., Liu, F. & Ross, A. H. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate. J. Biol. Chem. 278, 33617–33620 (2003).
pubmed: 12857747 doi: 10.1074/jbc.C300296200
Walker, S. M., Leslie, N. R., Perera, N. M., Batty, I. H. & Downes, C. P. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem. J. 379, 301–307 (2004).
pubmed: 14711368 doi: 10.1042/bj20031839 pmcid: 1224073
Iijima, M., Huang, Y. E., Luo, H. R., Vazquez, F. & Devreotes, P. N. Novel mechanism of PTEN regulation by its phosphatidylinositol 4,5-bisphosphate binding motif is critical for chemotaxis. J. Biol. Chem. 279, 16606–16613 (2004).
pubmed: 14764604 doi: 10.1074/jbc.M312098200
Lee, J. O. et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99, 323–334 (1999).
pubmed: 10555148 doi: 10.1016/S0092-8674(00)81663-3
Vazquez, F., Ramaswamy, S., Nakamura, N. & Sellers, W. R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell Biol. 20, 5010–5018 (2000).
pubmed: 10866658 doi: 10.1128/MCB.20.14.5010-5018.2000 pmcid: 85951
Torres, J. & Pulido, R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276, 993–998 (2001).
pubmed: 11035045 doi: 10.1074/jbc.M009134200
Henager, S. H. et al. Enzyme-catalyzed expressed protein ligation. Nat. Methods 13, 925–927 (2016).
pubmed: 27669326 doi: 10.1038/nmeth.4004 pmcid: 5088058
Bolduc, D. et al. Phosphorylation-mediated PTEN conformational closure and deactivation revealed with protein semisynthesis. eLife 2, e00691 (2013).
pubmed: 23853711 doi: 10.7554/eLife.00691 pmcid: 3707082
Al-Khouri, A. M., Ma, Y., Togo, S. H., Williams, S. & Mustelin, T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3β. J. Biol. Chem. 280, 35195–35202 (2005).
pubmed: 16107342 doi: 10.1074/jbc.M503045200
Dempsey, D. R. & Cole, P. A. Protein chemical approaches to understanding PTEN lipid phosphatase regulation. Methods Enzymol. 607, 405–422 (2018).
pubmed: 30149868 doi: 10.1016/bs.mie.2018.05.007 pmcid: 6231048
Chen, Z. et al. Molecular features of phosphatase and tensin homolog (PTEN) regulation by C-terminal phosphorylation. J. Biol. Chem. 291, 14160–14169 (2016).
pubmed: 27226612 doi: 10.1074/jbc.M116.728980 pmcid: 4933174
Masson, G. R., Perisic, O., Burke, J. E. & Williams, R. L. The intrinsically disordered tails of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity. Biochem. J. 473, 135–144 (2016).
pubmed: 26527737 doi: 10.1042/BJ20150931
Das, S., Dixon, J. E. & Cho, W. Membrane-binding and activation mechanism of PTEN. Proc. Natl Acad. Sci. USA 100, 7491–7496 (2003).
pubmed: 12808147 doi: 10.1073/pnas.0932835100 pmcid: 164614
Chen, Z. et al. Enzymatic analysis of PTEN ubiquitylation by WWP2 and NEDD4-1 E3 ligases. Biochemistry 55, 3658–3666 (2016).
pubmed: 27295432 doi: 10.1021/acs.biochem.6b00448
Nguyen, H. N. et al. Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium. Oncogene 33, 5688–5696 (2014).
pubmed: 24292679 doi: 10.1038/onc.2013.507
Rahdar, M. et al. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc. Natl Acad. Sci. USA 106, 480–485 (2009).
pubmed: 19114656 doi: 10.1073/pnas.0811212106
Dempsey, D. R., Jiang, H., Kalin, J. H., Chen, Z. & Cole, P. A. Site-specific protein labeling with N-hydroxysuccinimide-esters and the analysis of ubiquitin ligase mechanisms. J. Am. Chem. Soc. 140, 9374–9378 (2018).
pubmed: 30016585 doi: 10.1021/jacs.8b05098 pmcid: 6093203
Nguyen, H. N. et al. Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities. Proc. Natl Acad. Sci. USA 111, E2684–E2693 (2014).
pubmed: 24979808 doi: 10.1073/pnas.1409433111 pmcid: 4084459
Muir, T. W., Sondhi, D. & Cole, P. A. Expressed protein ligation: a general method for protein engineering. Proc. Natl Acad. Sci. USA 95, 6705–6710 (1998).
pubmed: 9618476 doi: 10.1073/pnas.95.12.6705 pmcid: 22605
Henager, S. H., Henriquez, S., Dempsey, D. R. & Cole, P. A. Analysis of site-specific phosphorylation of PTEN by using enzyme-catalyzed expressed protein ligation. Chembiochem 21, 64–68 (2020).
pubmed: 31206229 doi: 10.1002/cbic.201900316
Murata, Y., Iwasaki, H., Sasaki, M., Inaba, K. & Okamura, Y. Phosphoinositide phosphatase activity coupled to an intrinsic voltage sensor. Nature 435, 1239–1243 (2005).
pubmed: 15902207 doi: 10.1038/nature03650
Iwasaki, H. et al. A voltage-sensing phosphatase, Ci-VSP, which shares sequence identity with PTEN, dephosphorylates phosphatidylinositol 4,5-bisphosphate. Proc. Natl Acad. Sci. USA 105, 7970–7975 (2008).
pubmed: 18524949 doi: 10.1073/pnas.0803936105 pmcid: 2430346
Matsuda, M. et al. Crystal structure of the cytoplasmic phosphatase and tensin homolog (PTEN)-like region of Ciona intestinalis voltage-sensing phosphatase provides insight into substrate specificity and redox regulation of the phosphoinositide phosphatase activity. J. Biol. Chem. 286, 23368–23377 (2011).
pubmed: 21543329 doi: 10.1074/jbc.M110.214361 pmcid: 3123101
Liu, L. et al. A glutamate switch controls voltage-sensitive phosphatase function. Nat. Struct. Mol. Biol. 19, 633–641 (2012).
pubmed: 22562138 doi: 10.1038/nsmb.2289 pmcid: 3529583
Wei, Y., Stec, B., Redfield, A. G., Weerapana, E. & Roberts, M. F. Phospholipid-binding sites of phosphatase and tensin homolog (PTEN): exploring the mechanism of phosphatidylinositol 4,5-bisphosphate activation. J. Biol. Chem. 290, 1592–1606 (2015).
pubmed: 25429968 doi: 10.1074/jbc.M114.588590
Jang, H., Smith, I., Eng, C. & Nussinov, R. The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane. iScience 24, 102438 (2021).
pubmed: 34113810 doi: 10.1016/j.isci.2021.102438 pmcid: 8169795
Rayaprolu, V., Royal, P., Stengel, K., Sandoz, G. & Kohout, S. C. Dimerization of the voltage-sensing phosphatase controls its voltage-sensing and catalytic activity. J. Gen Physiol. 150, 683–696 (2018).
pubmed: 29695412 doi: 10.1085/jgp.201812064 pmcid: 5940254
Salzmann, M., Pervushin, K., Wider, G., Senn, H. & Wuthrich, K. TROSY in triple-resonance experiments: new perspectives for sequential NMR assignment of large proteins. Proc. Natl Acad. Sci. USA 95, 13585–13590 (1998).
pubmed: 9811843 doi: 10.1073/pnas.95.23.13585 pmcid: 24862
Coote, P. W. et al. Optimal control theory enables homonuclear decoupling without Bloch–Siegert shifts in NMR spectroscopy. Nat. Commun. 9, 3014 (2018).
pubmed: 30069002 doi: 10.1038/s41467-018-05400-4 pmcid: 6070575
Dubey, A., Kadumuri, R. V., Jaipuria, G., Vadrevu, R. & Atreya, H. S. Rapid NMR assignments of proteins by using optimized combinatorial selective unlabeling. Chembiochem 17, 334–340 (2016).
pubmed: 26662553 doi: 10.1002/cbic.201500513
Kleiger, G., Saha, A., Lewis, S., Kuhlman, B. & Deshaies, R. J. Rapid E2-E3 assembly and disassembly enable processive ubiquitylation of cullin-RING ubiquitin ligase substrates. Cell 139, 957–968 (2009).
pubmed: 19945379 doi: 10.1016/j.cell.2009.10.030 pmcid: 2804849
Santiago-Frangos, A., Jeliazkov, J. R., Gray, J. J. & Woodson, S. A. Acidic C-terminal domains autoregulate the RNA chaperone Hfq. eLife 6, e27049 (2017).
pubmed: 28826489 doi: 10.7554/eLife.27049 pmcid: 5606850
de Vries, S. J., van Dijk, M. & Bonvin, A. M. The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 5, 883–897 (2010).
pubmed: 20431534 doi: 10.1038/nprot.2010.32
van Zundert, G. C. P. et al. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 428, 720–725 (2016).
pubmed: 26410586 doi: 10.1016/j.jmb.2015.09.014
Chu, N. et al. The structural determinants of PH domain-mediated regulation of Akt revealed by segmental labeling. eLife 9, e59151 (2020).
pubmed: 32744507 doi: 10.7554/eLife.59151 pmcid: 7438110
Liu, D., Xu, R. & Cowburn, D. Segmental isotopic labeling of proteins for nuclear magnetic resonance. Methods Enzymol. 462, 151–175 (2009).
pubmed: 19632474 doi: 10.1016/S0076-6879(09)62008-5
Rabenstein, D. L. Heparin and heparan sulfate: structure and function. Nat. Prod. Rep. 19, 312–331 (2002).
pubmed: 12137280 doi: 10.1039/b100916h
Johnston, S. B. & Raines, R. T. Catalysis by the tumor-suppressor enzymes PTEN and PTEN-L. PLoS ONE 10, e0116898 (2015).
pubmed: 25607987 doi: 10.1371/journal.pone.0116898 pmcid: 4301912
Gil, A. et al. A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity. PLoS ONE 10, e0119287 (2015).
pubmed: 25875300 doi: 10.1371/journal.pone.0119287 pmcid: 4398541
Mighell, T. L., Evans-Dutson, S. & O’Roak, B. J. A saturation mutagenesis approach to understanding PTEN lipid phosphatase activity and genotype-phenotype relationships. Am. J. Hum. Genet. 102, 943–955 (2018).
pubmed: 29706350 doi: 10.1016/j.ajhg.2018.03.018 pmcid: 5986715
Padua, R. A. P. et al. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nat. Commun. 9, 4507 (2018).
pubmed: 30375376 doi: 10.1038/s41467-018-06814-w pmcid: 6207724
Whittier, S. K. & Loria, J. P.
pubmed: 24026965 doi: 10.1007/s12104-013-9524-0
Choy, M. S. et al. Conformational rigidity and protein dynamics at distinct timescales regulate PTP1B activity and allostery. Mol. Cell 65, 644–658 (2017).
pubmed: 28212750 doi: 10.1016/j.molcel.2017.01.014 pmcid: 5325675
McConnachie, G., Pass, I., Walker, S. M. & Downes, C. P. Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. Biochem. J. 371, 947–955 (2003).
pubmed: 12534371 doi: 10.1042/bj20021848 pmcid: 1223325
Maccario, H., Perera, N. M., Davidson, L., Downes, C. P. & Leslie, N. R. PTEN is destablized by phosphorylation on Thr 366. Biochem. J. 405, 439–444 (2007).
pubmed: 17444818 doi: 10.1042/BJ20061837 pmcid: 2267318
Miller, M. S. et al. Getting the most out of your crystals: data collection at the new high-flux, microfocus MX beamlines at NSLS-II. Molecules 24, 496 (2019).
doi: 10.3390/molecules24030496 pmcid: 6384729
Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
pubmed: 20124692 doi: 10.1107/S0907444909047337 pmcid: 2815665
Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214 (2013).
pubmed: 23793146 doi: 10.1107/S0907444913000061 pmcid: 3689523
Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255 (1997).
pubmed: 15299926 doi: 10.1107/S0907444996012255
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
pubmed: 20383002 doi: 10.1107/S0907444910007493 pmcid: 2852313
Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).
pubmed: 17681537 doi: 10.1016/j.jmb.2007.05.022
Nikolovska-Coleska, Z. et al. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal. Biochem. 332, 261–273 (2004).
pubmed: 15325294 doi: 10.1016/j.ab.2004.05.055
Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
pubmed: 8520220 doi: 10.1007/BF00197809
Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 (2005).
pubmed: 15815974 doi: 10.1002/prot.20449
Hyberts, S. G., Milbradt, A. G., Wagner, A. B., Arthanari, H. & Wagner, G. Application of iterative soft thresholding for fast reconstruction of NMR data non-uniformly sampled with multidimensional Poisson gap scheduling. J. Biomol. NMR 52, 315–327 (2012).
pubmed: 22331404 doi: 10.1007/s10858-012-9611-z pmcid: 3321367
Schanda, P. & Brutscher, B. Very fast two-dimensional NMR spectroscopy for real-time investigation of dynamic events in proteins on the time scale of seconds. J. Am. Chem. Soc. 127, 8014–8015 (2005).
pubmed: 15926816 doi: 10.1021/ja051306e
Schumann, F. H. et al. Combined chemical shift changes and amino acid specific chemical shift mapping of protein-protein interactions. J. Biomol. NMR 39, 275–289 (2007).
pubmed: 17955183 doi: 10.1007/s10858-007-9197-z
Khatib, F. et al. Algorithm discovery by protein folding game players. Proc. Natl Acad. Sci. USA 108, 18949–18953 (2011).
pubmed: 22065763 doi: 10.1073/pnas.1115898108 pmcid: 3223433
Marty, M. T. et al. Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles. Anal. Chem. 87, 4370–4376 (2015).
pubmed: 25799115 doi: 10.1021/acs.analchem.5b00140 pmcid: 4594776

Auteurs

Daniel R Dempsey (DR)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Thibault Viennet (T)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

Reina Iwase (R)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Eunyoung Park (E)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

Stephanie Henriquez (S)

Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Zan Chen (Z)

Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Jeliazko R Jeliazkov (JR)

Departments of Chemical and Biomolecular Engineering and Biophysics, Johns Hopkins University, Baltimore, MD, USA.

Brad A Palanski (BA)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Kim L Phan (KL)

Departments of Medicine, Oncology, and Biophysics and Biophysical Chemistry, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Paul Coote (P)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

Jeffrey J Gray (JJ)

Departments of Chemical and Biomolecular Engineering and Biophysics, Johns Hopkins University, Baltimore, MD, USA.

Michael J Eck (MJ)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

Sandra B Gabelli (SB)

Departments of Medicine, Oncology, and Biophysics and Biophysical Chemistry, Johns Hopkins School of Medicine, Baltimore, MD, USA. gabelli@jhmi.edu.

Haribabu Arthanari (H)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. hari@hms.harvard.edu.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. hari@hms.harvard.edu.

Philip A Cole (PA)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. pacole@bwh.harvard.edu.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. pacole@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH